# Facilitating meniscus healing through SDF-1/CXCR4 axis modified cell-therapy

> **NIH NIH R21** · RHODE ISLAND HOSPITAL · 2021 · $171,787

## Abstract

PROJECT SUMMARY/ABSTRACT
Fibrocartilage tears in the avascular white-white zone of the meniscus are a significant clinical
challenges due to their inability to heal. These common injuries are independent risk factors for
the development of post-traumatic osteoarthritis. The long-term goal is to develop innovative
cellular biologic therapies geared to stimulate healing of white-white zone meniscus tears in
patients. Preliminary studies demonstrate that cartilage-derived mesenchymal progenitors
(CPCs) can be used as a cell-therapy to effectively repair meniscus tears in a rodent model.
However, since the long-term goal involves effectively treating human patients, there exists a
knowledge gap as to how the beneficial healing effect of CPCs can be scaled up to in order to
effectively repair menisci in larger animal models. The objective of this project to evaluate the
efficacy of CXCR4 gene modified CPC therapy as a means of facilitating white-white zone
tissue healing in a rabbit meniscus injury model. The central hypothesis is that treating white-
white zone meniscus tears with CPCs that have elevated chemokine receptor CXCR4 will
increase their cell localization to the site of injury and improve the extent and quality of the
resulting healing response. This central hypothesis will be tested by completing two specific
aims: (1) Measure the extent cell engraftment that results from gene delivery of CXCR4 into
CPCs; (2) Evaluate the efficacy of meniscus repair resulting from CXCR4 gene modified cell
therapy. The research design is to employ a gene delivery approach to modify the expression
of the chemokine receptor CXCR4, which is a regulator cell trafficking in response to injury, in
order to increase cell localization and engraftment to white-white zone meniscus injury sites. It is
expected that this will improve meniscus injury repair as measured by biomechanical tensile
testing and histology. Successful completion will have a positive impact by laying the
groundwork for developing an effective new strategy to stimulate meniscus injury repair through
the use of cellular biologics. This project is relevant to the mission of NIAMS because it seeks
to find innovative ways to treat musculoskeletal injuries and prevent arthritis.

## Key facts

- **NIH application ID:** 10132243
- **Project number:** 5R21AR077326-02
- **Recipient organization:** RHODE ISLAND HOSPITAL
- **Principal Investigator:** Chathuraka Teekshana Jayasuriya
- **Activity code:** R21 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $171,787
- **Award type:** 5
- **Project period:** 2020-04-01 → 2023-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10132243

## Citation

> US National Institutes of Health, RePORTER application 10132243, Facilitating meniscus healing through SDF-1/CXCR4 axis modified cell-therapy (5R21AR077326-02). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10132243. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*